Invest
And Support A Brighter Future
Transform cancer treatment with us—enhancing existing therapies with our light-activated nanomedice that makes cancer treatment safer and effective.
Venture Capital & Investors
We are seeking €5 million to advance from preclinical phase to the IND-ready/CTA phase, with colorectal cancer as our first target indication.
Investors gain a clear, structured investment approach, with regular updates as we progress toward market entry, making this an impactful and transparent opportunity.
Pharmaceutical Companies
A sub-licence for specific type of cancer that fits your portfolio. Our drug as payload to your targeting therapeutic or transform your imaging device into intervention device with precision treatment.
Together
Crowd funding
We are seeking €2 million to match with 3M on convertable loans in order to get a convincing preclinical dataset to convince partners to run clinical trails.
Supporters receive regular updates, invitations to exclusive events, and can witness how their contribution drives our work toward a medical breakthrough.
Donations
With a donation of €1000 or more, supporters can join our community and help fund our research and development.
Make impact . Together we push the bounderies of what is possible in precision oncology.
How Your Investment Will Be Utilized
Your investment will be strategically allocated to:
Clinical Trials
Launching studies to assess the safety and efficacy of our light-activated therapies across diverse cancer types.
Product Scaling
Building robust facilities to support large-scale production of our innovative treatment.
Market Integration
Establishing partnerships with healthcare networks and oncology clinics to integrate our therapies alongside standard treatments.
Key Milestones
Incubator Programs
Successfully completed the Venture Academy (2023) and unlock_ incubator program (2024) at BioScience Park in Leiden, equipping us with essential resources and connections.
Funding Support
Libertatis Ergo Holding B.V. (ELF) has contributed €35,000 to support our mission of bringing these therapies to market.
Academic Partnerships
Collaborated with Leiden University’s Faculty of Medicine, securing €200,000 in funding for research on light-activated drugs.
Patent Agreement
LURIS, the patent office of Leiden University, will hold a 15% equity stake in Genlumina, reflecting the innovative nature of our technology.
Key Milestones
Academic Partnerships
Collaborated with Leiden University’s Faculty of Medicine, securing €200,000 in funding for research on light-activated drugs.
Incubator Programs
Successfully completed the Venture Academy (2023) and unlock_ incubator program (2024) at BioScience Park in Leiden, equipping us with essential resources and connections.
Patent Agreement
LURIS, the patent office of Leiden University, will hold a 15% equity stake in Genlumina, reflecting the innovative nature of our technology.
Funding Support
Libertatis Ergo Holding B.V. (ELF) has contributed €35,000 to support our mission of bringing these therapies to market.
Convertable Loan
UNIIQ has contributed €350,000 to support our mission of bringing these therapies to market.
Our technology pushes the boundaries of what’s possible in precision oncology.